Cores for technetium radiopharmaceuticals
    1.
    发明授权
    Cores for technetium radiopharmaceuticals 失效
    锝放射性药物的核心

    公开(公告)号:US06329513B1

    公开(公告)日:2001-12-11

    申请号:US09568550

    申请日:2000-05-11

    IPC分类号: C07F500

    CPC分类号: C07B59/004

    摘要: A 99mTc complex which contains the moiety Tc═NR, Tc—N═NY or Tc(—N═NY)2, and as a synthetic organic ligand which confers biological target-seeking properties on the technetium complex, where: R is an aryl group, a substituted or unsubstituted alkyl group or the group —NR1R2; Y is an aryl group or a substituted or unsubstituted alkyl group; R1 and R2 are H, aryl groups or substituted or unsubstituted aliphatic or cyclic alkyl groups, and are the same or different provided that both are not hydrogen; where at least one of the R or Y groups comprises an aryl group which chelates the 99mTc.

    摘要翻译: 包含部分Tc = NR,Tc-N = NY或Tc(-N = NY)2的99mTc复合物,以及赋予锝络合物上的生物寻靶特性的合成有机配体,其中:R是芳基 基团,取代或未取代的烷基或基团-NR1R2; Y是芳基或取代或未取代的烷基; R1和R2是H,芳基或取代或未取代的脂族或环状烷基,并且相同或 不同的是两者都不是氢;其中R或Y基团中的至少一个包括螯合99mTc的芳基。

    Cores for technetium radiopharmaceuticals
    2.
    发明授权
    Cores for technetium radiopharmaceuticals 失效
    锝放射性药物的核心

    公开(公告)号:US6124440A

    公开(公告)日:2000-09-26

    申请号:US431098

    申请日:1999-11-01

    CPC分类号: C07B59/004

    摘要: .sup.99m Tc complexes of formula L.sub.n Tc.dbd.NR, L.sub.n Tc--N.dbd.NY, or L.sub.n Tc--(N.dbd.NY).sub.2 wherein each L is independently a monodentate or multidentate ligand;Y is a substituted or unsubstituted aryl group or substituted or unsubstituted alkyl group;R is Y or the grouping --NR.sup.1 R.sup.2 ;n is 1-4;where at least one of R or Y is combined with one or more of the L groups; R.sup.1 and R.sup.2 are H, substituted or unsubstituted aryl groups or substituted or unsubstituted aliphatic or cyclic alkyl groups, and are the same or different, provided that both are not hydrogen.

    摘要翻译: 式LnTc = NR,LnTc-N = NY或LnTc-(N = NY)2的99mTc配合物,其中每个L独立地是单齿或多齿配体; Y是取代或未取代的芳基或取代或未取代的烷基; R为Y或分组-NR1R2; n为1-4; 其中R或Y中的至少一个与一个或多个L基团组合; R 1和R 2是H,取代或未取代的芳基或取代或未取代的脂族或环状烷基,并且相同或不同,条件是两者都不是氢。

    Cores for technetium radiopharmaceuticals
    3.
    发明授权
    Cores for technetium radiopharmaceuticals 失效
    锝放射性药物的核心

    公开(公告)号:US06515112B2

    公开(公告)日:2003-02-04

    申请号:US09976014

    申请日:2001-10-15

    IPC分类号: C07F500

    CPC分类号: C07B59/004

    摘要: A 99mTc complex which contains the moiety Tc═NR, Tc—N═NY or Tc(—N═NY)2, and as a synthetic organic ligand which confers biological target-seeking properties on the technetium complex, where: R is an aryl group, a substituted or unsubstituted alkyl group or the group —NR1R2; Y is an aryl group or a substituted or unsubstituted alkyl group; R1 and R2 are H, aryl groups or substituted or unsubstituted aliphatic or cyclic alkyl groups, and are the same or different provided that both are not hydrogen; where at least one of the R or Y groups comprises an aryl group which chelates the 99mTc.

    摘要翻译: 包含部分Tc = NR,Tc-N = NY或Tc(-N = NY)2的99mTc复合物,以及赋予锝络合物上的生物寻靶特性的合成有机配体,其中:R是芳基 基团,取代或未取代的烷基或基团-NR1R2; Y是芳基或取代或未取代的烷基; R1和R2是H,芳基或取代或未取代的脂族或环状烷基,并且相同或 不同的是两者都不是氢;其中R或Y基团中的至少一个包括螯合99mTc的芳基。

    Cores for technetium radiopharmaceuticals
    5.
    发明授权
    Cores for technetium radiopharmaceuticals 失效
    锝放射性药物的核心

    公开(公告)号:US6001979A

    公开(公告)日:1999-12-14

    申请号:US774299

    申请日:1996-12-24

    CPC分类号: C07B59/004

    摘要: A synth .sup.99m Tc complex which contains the moiety Tc.dbd.NR, Tc--N.dbd.NY or Tc(--N.dbd.NY).sub.2 and an organic ligand which confers biological target-seeking properties on the technetium complex, where R is an aryl group, a substituted or unsubstituted alkyl group or the group --NR.sup.1 R.sup.2 ; Y is an aryl group or a substituted or unsubstituted alkyl group; and R.sup.1 and R.sup.2 are H, aryl groups or substituted or unsubstituted aliphatic or cyclic alkyl groups, and are the same or different provided that both are not hydrogen. Radiopharmaceuticals comprising this complex are also described, together with methods for the preparation of the complex.

    摘要翻译: 包含部分Tc = NR,Tc-N = NY或Tc(-N = NY)2的合成99mTc复合物和赋予锝络合物上的生物寻靶特性的有机配体,其中R是芳基, 取代或未取代的烷基或基团-NR1R2; Y是芳基或取代或未取代的烷基; 并且R 1和R 2是H,芳基或取代或未取代的脂族或环状烷基,并且相同或不同,条件是两者不是氢。 还描述了包含该复合物的放射性药物,以及制备复合物的方法。

    Cores for technetium radiopharmaceuticals
    6.
    发明授权
    Cores for technetium radiopharmaceuticals 失效
    锝放射性药物的核心

    公开(公告)号:US5589576A

    公开(公告)日:1996-12-31

    申请号:US289654

    申请日:1994-08-12

    IPC分类号: A61K51/04 C07F13/00

    摘要: Novel complexes of technetium (.sup.99 Tc or .sup.99m Tc) which contain the moiety Tc.dbd.NR, Tc--N.dbd.NY or Tc(--N.dbd.NY).sub.2, and a ligand which confers biological target-seeking properties on the complex, wherein R represents an aryl group, a substituted or unsubstituted alkyl group, or the grouping .dbd.NR.sup.1 R.sup.2 ; Y represents an aryl group or a substituted or unsubstituted alkyl group; and R.sup.1 and R.sup.2 are hydrogen, aryl groups or substituted or unsubstituted aliphatic or cyclic alkyl groups, and may be both the same or different, provided that both are not hydrogen. The complexes are suitable for use in radiopharmaceuticals for a variety of clinical applications. Methods for the preparation of these technetium complexes are also described.

    摘要翻译: 含有部分Tc = NR,Tc-N = NY或Tc(-N = NY)2的锝(99Tc或99mTc)的新型络合物和赋予复合物生物靶寻求性质的配体,其中R表示 芳基,取代或未取代的烷基,或基团= NR 1 R 2; Y表示芳基或取代或未取代的烷基; 并且R 1和R 2是氢,芳基或取代或未取代的脂族或环状烷基,并且可以相同或不同,条件是两者都不是氢。 该配合物适用于各种临床应用的放射性药物。 还描述了制备这些锝络合物的方法。

    Complexes of TC99m radiopharmaceuticals
    7.
    发明授权
    Complexes of TC99m radiopharmaceuticals 失效
    TC99M放射技术的复合物

    公开(公告)号:US5081232A

    公开(公告)日:1992-01-14

    申请号:US194285

    申请日:1988-05-16

    摘要: Complexes useful as radiopharmaceuticals contain the .sup.99m Tc-NO moiety and up to four organic ligands which confer biological target-seeking properties on the complex. Preferred are mono-cationic complexes, particularly having the formula[.sup.99m Tc(NO)L.sub.2 X].sup.+where X is halide or pseudohalide and L is a bidentate ligand for Technetium, which have interesting properties for use as heart visualizing agents. Examples of ligands include di-(dialkyl and diphenyl)phosphinoethanes and o-phenylenebisdimethylarsine. The complexes may be made by reacting generator eluate pertechnetate with a hydroxylamine salt and with the ligands, preferably in a single step by providing a reaction mixture containing the three reagents optionally in the presence of a reducing agent.